Most hospitalised patients with type 2 diabetes benefit from continuous glucose monitoring compared to point‐of‐care glucose testing in a non‐intensive care unit setting: A heterogeneity of treatment effect analysis

作者：Mikkel Thor Olsen, Signe Hjejle Jensen, Louise Mathorne Rasmussen, Carina Kirstine Klarskov, Birgitte Lindegaard, Jonas Askø Andersen, Hans Gottlieb, Suzanne Lunding, Katrine Bagge Hansen, Ulrik Pedersen‐Bjergaard, Peter Lommer Kristensen · 发表于：Diabetes Obesity and Metabolism · 年份：2025 · DOI：10.1111/dom.16297 · 被引用次数：6 · 研究领域：Hyperglycemia and glycemic control in critically ill and hospitalized patients、Diabetes Management and Research、Diabetes Treatment and Management

AIMS: Understanding whether improved glycaemic outcomes from continuous glucose monitoring (CGM) compared to point-of-care (POC) glucose testing apply uniformly to all hospitalised non-intensive care unit (non-ICU) patients with type 2 diabetes or vary among subgroups is crucial for allocating healthcare resources. MATERIALS AND METHODS: This two-site randomised controlled trial DIAbetes TEam and Cgm (DIATEC) enrolled 166 non-ICU patients with type 2 diabetes. Diabetes management was based on either POC glucose testing or CGM. Diabetes management was carried out by general hospital staff, under the guidance of specialised diabetes teams, using insulin titration protocols in both groups. We conducted heterogeneity of treatment effect regression analyses to assess whether certain patient characteristics (e.g., age, gender, haemoglobin A1c, etc.) modified the effects of CGM, compared to POC glucose testing, on the glycaemic outcomes time in/above/below range, mean glucose level, standard deviation (SD), coefficient of variation (CV) and hypoglycaemic events. RESULTS: No heterogeneity of treatment effect was observed, suggesting that all patients benefited equally from CGM compared to POC glucose testing regarding glycaemic outcomes. CONCLUSIONS: From a glycaemic perspective, CGM could be widely recommended for most non-ICU patients with type 2 diabetes, as its glycaemic benefits over POC glucose testing appear consistent regardless of individual characteristics.